This supports the view of IL1 and IL23 as a promising target for those patients that fail to respond to TNFα inhibition, the standard of care for many severe inflammatory mediated diseases, including inflammatory bowel disease (IBD). Here, IL1A is linked to inflammatory bowel disease.